Read by QxMD icon Read

Clinical Lymphoma, Myeloma & Leukemia

Jean El-Cheikh, Nour M Moukalled, Haidar El Darsa, Radwan Massoud, Souha S Kanj, Rami Mahfouz, Ali Bazarbachi
No abstract text is available yet for this article.
August 27, 2018: Clinical Lymphoma, Myeloma & Leukemia
Aleš Obr, Vít Procházka, Andrea Jirkuvová, Helena Urbánková, Eva Kriegova, Petra Schneiderová, Michaela Vatolíková, Tomáš Papajík
BACKGROUND: TP53 mutation (TP53mut) and a complex karyotype (CK) were shown to be predictors of poor outcome in mantle-cell lymphoma (MCL). In this study we examined the combined effect of both of these risk factors. PATIENTS AND METHODS: Patients diagnosed with MCL between January 2000 and December 2014 (n = 74) were evaluated. Forty-eight of them had available material for TP53 and cytogenetic examination. We analyzed the prognostic effect of combined TP53mut and CK in the cohort of patients treated with rituximab-containing therapy...
August 23, 2018: Clinical Lymphoma, Myeloma & Leukemia
Stephen B Heitner, Jessica Minnier, Aynun Naher, Ryan Van Woerkem, Alexandra Ritts, Maros Ferencik, Craig Broberg, Eva Medvedova, Rebecca Silbermann, Emma C Scott
BACKGROUND: Proteasome inhibitors used in the treatment of multiple myeloma act primarily through the disruption of intrinsic cellular protein quality maintenance, resulting in proteotoxic stress, cellular dysfunction, and, ultimately, cell death. We assessed whether evidence has shown off-target myocardial dysfunction related to the administration of bortezomib-based chemotherapy for multiple myeloma. PATIENTS AND METHODS: Patients aged 18 to 70 years who were free of significant cardiovascular disease were included...
August 14, 2018: Clinical Lymphoma, Myeloma & Leukemia
Amit Reddy, Ingrid Espinoza, Dana Cole, Jason Schallheim, Teja Poosarla, Eldrin Bhanat, Yunyun Zhou, Jovanny Zabaleta, Gail Megason, Christian R Gomez
BACKGROUND: The survival of patients with B-acute lymphoblastic leukemia (B-ALL) is significantly lower in African American (AA) children compared with European American children (EA). Here, we present a whole exome sequencing (WES) study showing race-specific genetic variations that may play a role on the disparate outcomes among AA and EA children with B-ALL. PATIENTS AND METHODS: Five AA and 15 EA patients ranging in age from 1 to 18 years were enrolled. The median blast percentage was 94...
August 14, 2018: Clinical Lymphoma, Myeloma & Leukemia
Olwen Westerland, Nishanth Sivarasan, Sarah Natas, Hema Verma, Sarah McElroy, Jessica M Winfield, Radhouene Neji, Inas El-Najjar, Majid Kazmi, Matthew Streetly, Vicky Goh
BACKGROUND: Whole body magnetic resonance imaging (WBMRI) is currently recommended by guidelines for the assessment of myeloma. This will inevitably result in incidental findings. We aimed to assess the frequency of extraskeletal incidental findings and the added value of contrast-enhanced (CE) T1-weighted (T1-W) and diffusion-weighted (DWI) sequences for their characterization in a single WBMRI examination. PATIENTS AND METHODS: We performed 1.5 T WBMRI in 100 patients (53 female; median age, 65 years) with plasma-cell disorders from January 2014 to July 2017...
August 13, 2018: Clinical Lymphoma, Myeloma & Leukemia
Xianrui Zhang, Meiyun Fang
TEMPI (telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, intrapulmonary shunting) syndrome is a newly described clinical entity that is generally considered a plasma cell dyscrasia with multiple system involvement. The etiology and pathophysiology of this condition remains elusive. Nevertheless, clonal plasma cells and monoclonal protein appear to be major contributors. The early diagnosis of TEMPI syndrome is essential because therapies targeting the underlying plasma cells can lead to a dramatic response...
August 9, 2018: Clinical Lymphoma, Myeloma & Leukemia
Weerapat Owattanapanich, Eakkapol Utchariyaprasit, Adisak Tantiworawit, Ekarat Rattarittamrong, Pimjai Niparuck, Teeraya Puavilai, Jakrawadee Julamanee, Pirun Saelue, Chantiya Chanswangphuwana, Chantana Polprasert, Wasithep Limvorapitak, Nonglak Kanitsap, Chinadol Wanitpongpun, Chajchawan Nakhakes, Chantarapa Sriswasdi, Kannadit Prayongratana
BACKGROUND: Elderly patients with acute myeloid leukemia (AML) have a poorer prognosis than younger ones. Several factors contribute to the poor outcomes for this patient group. PATIENTS AND METHODS: This study investigated the epidemiology, clinical characteristics, treatment, and clinical outcomes of elderly Thai patients with AML. This 3-year, prospective, multicenter study was focused on Thai patients with AML aged over 60 years who were diagnosed between 2014 and 2016...
August 8, 2018: Clinical Lymphoma, Myeloma & Leukemia
Kiyomi Mashima, Iekuni Oh, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Shin-Ichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Ken Omine, Kazuo Muroi, Yoshinobu Kanda
BACKGROUND: Wilms' tumor 1 (WT1) mRNA expression is a universal marker of minimal residual disease in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood WT1 mRNA levels to predict relapse in patients with AML in remission. PATIENTS AND METHODS: From April 2012 to May 2015, 131 patients with AML were admitted to our hospital. Among them, 55 were examined for WT1 mRNA at least 3 times during complete remission to assess minimal residual disease, and thus were included in the following analyses...
August 4, 2018: Clinical Lymphoma, Myeloma & Leukemia
Qingxiu Dang, Hong Zhou, Juan Qian, Li Yang, Jianfei Huang, Yaping Zhang, Wenyu Shi
INTRODUCTION: Lysosomal-associated membrane protein 1 (LAMP1) is a lysosomal and plasma membrane protein that contributes to tumor metastatic potential and differentiation. PATIENTS AND METHODS: We performed immunohistochemical staining to investigate LAMP1 protein expression levels in 122 diffuse large B-cell lymphoma (DLBCL) tumor samples and 45 reactive hyperplasia tissues. Correlations between LAMP1 expression, various clinicopathologic features, and patient prognosis were evaluated by univariate and multivariate analyses...
August 3, 2018: Clinical Lymphoma, Myeloma & Leukemia
Mohamed A Kharfan-Dabaja, Tea Reljic, Hemant S Murthy, Ernesto Ayala, Ambuj Kumar
INTRODUCTION: It is common practice to refer patients to transplantation centers for allogeneic hematopoietic cell transplantation (allo-HCT) for blastic plasmacytoid dendritic-cell neoplasm (BPDCN) despite lack of randomized controlled trials. We performed a systematic review to assess the totality of evidence pertaining to the efficacy of allo-HCT in BPDCN. METHODS: We searched the Cochrane, PubMed, and Embase databases through January 5, 2018, for studies on allo-HCT for BPDCN...
August 2, 2018: Clinical Lymphoma, Myeloma & Leukemia
Joseph Mock, Paul R Kunk, Surabhi Palkimas, Jeremy M Sen, Michael Devitt, Bethany Horton, Craig A Portell, Michael E Williams, Hillary Maitland
BACKGROUND: The Bruton tyrosine kinase inhibitor, ibrutinib, is an effective therapy against mature B-cell malignancies. Although generally well tolerated, serious bleeding emerged during developmental clinical trials as an unexpected, although uncommon, adverse event. As the use of ibrutinib increases outside of the clinical trial setting and in patients with more comorbidities, the rate of major bleeding could be greater. MATERIALS AND METHODS: A retrospective analysis the data from all patients at our center and its regional clinics who had been prescribed ibrutinib from January 2012 to May 2016 were reviewed for demographic data, comorbid illnesses, bleeding events, and concurrent medications...
August 1, 2018: Clinical Lymphoma, Myeloma & Leukemia
Devin R Broadwater, Joanna L Conant, David R Czuchlewski, Jordan M Hall, Shi Wei, Gene P Siegal, Deniz Peker
INTRODUCTION: Histiocytic sarcoma (HS) is a rare malignant neoplasm that can occur in patients with a history of treatment for hematologic or solid tumors. Because no optimal treatment has been defined and standardized, the treatment modalities used and outcomes reported have been highly variable. In the present study, 3 major institutions explored the clinicopathologic features of de novo and secondary HS. MATERIALS AND METHODS: After institutional review board approval, clinical, histopathologic, and immunophenotypic data were collected from patients with a diagnosis of HS and treated at the University of Alabama at Birmingham, University of New Mexico, or Brooke Army Medical Center from January 1, 2003 to December 31, 2016...
August 1, 2018: Clinical Lymphoma, Myeloma & Leukemia
Benjamin Heyman, Anne Beaven
No abstract text is available yet for this article.
August 1, 2018: Clinical Lymphoma, Myeloma & Leukemia
Chetasi Talati, David Sallman, Alan F List
Myelodysplastic syndrome (MDS) with deletion 5q [del(5q)] is a distinct clinical and pathologic disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Lenalidomide resistance, including primary resistance, occurs by clonal evolution, which is frequently attributable to the presence of somatic mutations in the DNA-binding domain of the TP53 gene. The treatment options after development of resistance to lenalidomide are limited and consist of hypomethylating agents, clinical trials, and allogeneic hematopoietic stem cell transplantation...
July 30, 2018: Clinical Lymphoma, Myeloma & Leukemia
Benjamin Heyman, David Rizzieri, David J Adams, Carlos De Castro, Louis Diehl, Zhiguo Li, Joseph Moore, Anne Beaven
BACKGROUND: For patients with aggressive lymphomas who relapse after initial therapy, a durable response is rarely achieved with standard salvage therapies. Significant efforts have focused on the development of novel treatments with reduced toxicity. We conducted a phase I prospective single arm clinical trial of the novel combination of BuRP (bendamustine, rituximab, and pixantrone) in patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: Eligible patients included adults with biopsy-proven R/R B-cell NHL who met the criteria for treatment...
July 29, 2018: Clinical Lymphoma, Myeloma & Leukemia
Sandy W Wong, Ute Hegenbart, Giovanni Palladini, Gunjan L Shah, Heather J Landau, Melissa Warner, Denis Toskic, Arnaud Jaccard, Timon Hansen, Joan Bladé, M Teresa Cibeira, Efstathios Kastritis, Angela Dispenzieri, Ashutosh Wechalekar, Cindy Varga, Stefan O Schönland, Raymond L Comenzo
INTRODUCTION: Deletion 17p (del 17p) portends a poor prognosis in myeloma, but its significance in light-chain amyloidosis is unknown. PATIENTS AND METHODS: We identified patients with light-chain amyloidosis and del 17p at diagnosis, and analyzed presenting characteristics, treatments, and clinical outcomes. All had baseline biopsy results showing amyloid and serologic and marrow studies, including standard fluorescence in-situ hybridization determinations of del 17p using commercial probes...
July 25, 2018: Clinical Lymphoma, Myeloma & Leukemia
Wasithep Limvorapitak, Michael J Barnett, Donna E Hogge, Donna L Forrest, Thomas J Nevill, Sujaatha Narayanan, Maryse M Power, Stephen H Nantel, Raewyn Broady, Kevin W Song, Cynthia L Toze, Yasser Abou Mourad, Heather J Sutherland, Alina S Gerrie, Jennifer White, David S Sanford
INTRODUCTION: Optimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia remains an area of ongoing research. We aimed to retrospectively compare outcomes following autologous stem cell transplantation (autoSCT) with allogeneic SCT (alloSCT) and consolidation chemotherapy (CMT) in patients with intermediate-risk karyotype AML in first complete remission. PATIENTS AND METHODS: We compared overall survival (OS) and leukemia-free survival (LFS) using propensity score (PS)-adjusted analysis of patients receiving PRT with autoSCT, matched sibling (MSD) alloSCT, unrelated/mismatch (UD/MM) alloSCT, and CMT...
July 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
Daisuke Hidaka, Masahiro Onozawa, Junichi Hashiguchi, Naohiro Miyashita, Kohei Kasahara, Shinichi Fujisawa, Eiko Hayase, Kohei Okada, Souichi Shiratori, Hideki Goto, Junichi Sugita, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Tomoyuki Endo, Satoshi Yamamoto, Yutaka Tsutsumi, Yoshihito Haseyama, Takahiro Nagashima, Akio Mori, Shuichi Ota, Hajime Sakai, Toshimichi Ishihara, Kiyotoshi Imai, Takuto Miyagishima, Yasutaka Kakinoki, Mitsutoshi Kurosawa, Hajime Kobayashi, Hiroshi Iwasaki, Chikara Shimizu, Takeshi Kondo, Takanori Teshima
BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. The aim of the present study was to determine the correlations of WT1 expression at the diagnosis of AML with established prognostic alterations. PATIENTS AND METHODS: We analyzed diagnostic bone marrow samples from 252 patients. WT1 expression, single nucleotide polymorphism (SNP) in the WT1 gene (rs16754), and Fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation were analyzed for all patients...
July 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
Urmeel H Patel, Joseph J Drabick, Jozef Malysz, Giampaolo Talamo
BACKGROUND: Multiple myeloma (MM) is characterized by the secretion of monoclonal protein by malignant plasma cells in the vast majority of cases. We identified and analyzed patterns of disease relapse and progression associated with disappearance of the paraprotein ("nonsecretory [NS] escape"), or conversion from production of intact Ig molecule to its associated light chain ("LC escape"). PATIENTS AND METHODS: We retrospectively reviewed medical records and a database of 791 consecutive patients with symptomatic MM...
July 4, 2018: Clinical Lymphoma, Myeloma & Leukemia
Pradnya Chopade, Luke P Akard
Most patients with chronic myeloid leukemia (CML) receiving treatment with BCR-ABL1 tyrosine kinase inhibitors (TKIs) will achieve favorable responses. Moreover, TKI therapy enables patients to experience long-term survival, with survival rates similar to those of individuals without CML. This enhanced survival has resulted from the availability of multiple BCR-ABL1 TKIs with efficacy, not only in frontline treatment, but, importantly, also in second- and third-line treatment. We have reviewed the changes in long-term outcomes in the era of TKI therapy and how these changes have affected treatment practices...
July 4, 2018: Clinical Lymphoma, Myeloma & Leukemia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"